MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. (MIST) is confirmed to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.22 per share.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.